Avacopan (granulomatosis with polyangiitis or microscopic polyangiitis; in combination with rituximab or cyclophosphamide)


  • Active Substance: Avacopan
  • Name: Tavneos®
  • Therapeutic area: Granulomatosis with polyangiitis or microscopic polyangiitis
  • Pharmaceutical company: Vifor Pharma Deutschland GmbH

Time table:

  • Start: 15.02.2022
  • Final decision by G-BA: 04.08.2022

Final decision:

  • Hint for a minor additional benefit